About US
Contact us
-
India's largest pharmacy group halts sales of Ranbaxy drugsBad news just keeps raining down onRanbaxy Laboratories. The Indian generics maker thought it had finally left its problems with U.S. regulators behind after its felony pleas and $500 million penalty2013/6/8
-
Scientists reveal malaria’s deadly binding mechanismThe binding mechanism that allows red blood cells infected with aggressive strains of malaria to stick to blood vessels has been discovered in a new study on children in Tanzania. Researchers from th2013/6/7
-
FDA official, panelists challenge Avandia safety trialDr. Thomas Marciniak, medical team leader of FDA's Division of Cardiovascular and Renal Products, made some expensive promises Wednesday morning. Before a panel of outside experts tasked with advising2013/6/7
-
Impax whacks jobs to try to right itself after Rytary delays cost it GSK dealImpax Laboratories' ($IPXL) is cutting roughly 10% of its workforce, or 110 jobs, after problems at its manufacturing plant in California cost it FDA consideration of a drug application and then a par2013/6/6
-
India's Cadila scouts Big Pharma partners to launch new diabetes drug abroadCadila Healthcarewants to partner with Big Pharma. The Indian drugmaker won domestic approval for a brand-new drug fordiabetics, Lipaglyn, that it's prepared to launch in its own country later this ye2013/6/6
-
3rd Excipient Festival China & Forum of International Drug Preparation & Pharmaceutical Excipient Development 2013’ has successfully come to an end3rd Excipient Festival China which hosted by CPEC, organized by PHEXCOM and co-organized by CPIA, Sichuan Pharmaceutical Association and West China School of Pharmacy Sichuan University has completed2013/6/5
-
Older drugs aren't just cheaper, they're better, study saysCritics contend that statistics blur important pharma breakthroughs Generic drugs already have cost on their side when competing with pricey brands. But according to a new study inHealth Affairs, old2013/6/5
-
Limited track-and-trace moves forward in U.S.The U.S. House of Representatives has advanced one step closer to delaying the tracking of individual drug units. A House bill passed today would direct theFDAto create national standards for monitori2013/6/5
-
GSK's kidney cancer drug delays ovarian cancer relapseGlaxoSmithKline's maintenance therapy Votrient delayed disease progression in patients with advanced epithelial ovarian cancer by an average of 5.6 months following front-line chemotherapy. In a Phas2013/6/4
-
Lilly blockbuster Alimta burned by more disappointing newsThere is bad news out of ASCO for Eli Lilly's ($LLY) Alimta, its blockbuster lung cancer drug that is already under a patent assault by Teva Pharmaceutical Industries ($TEVA). Lilly today announced t2013/6/4